[The clinical and pharmacoeconomic aspects of gemifloxacin(corrected) use in the patients with extra-hospital pneumonia in stationary conditions].
Zaĭtsev
A A
AA
Sinopal'nikova
A I
AI
D000328:Adult; D000900:Anti-Bacterial Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D003365:Costs and Cost Analysis; D017850:Economics, Pharmaceutical; D005260:Female; D024841:Fluoroquinolones / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D000077735:Gemifloxacin; D006801:Humans; D008297:Male; D009287:Naphthyridines / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000191:economics* / Q000382:microbiology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin